Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Jardiance, Synjardy, Glyxambi, Emplagliflozin/Linagliptin, Emplagliflozin/Metformin
Empagliflozin is an oral antidiabetic drug belonging to the sodium-glucose cotransporter 2 (SGLT2) inhibitor class. It works by blocking the reabsorption of glucose in the kidneys, leading to increased glucose excretion in the urine and lowering blood sugar levels. It is primarily used to improve glycemic control in adults with type 2 diabetes mellitus.
For improving glycemic control in adults with type 2 diabetes mellitus, reducing the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease, and for the treatment of heart failure with reduced ejection fraction.
Outcome:
Increased risk of acute kidney injury
Mechanism:
Additive effects on renal function
Outcome:
Increased risk of hypoglycemia
Mechanism:
Additive glucose-lowering effects
Outcome:
Reduced efficacy of empagliflozin
Mechanism:
NSAIDs can interfere with renal glucose excretion
Most likely new formulation: Combination therapy with other antidiabetic agents (2025, 75% confidence)
Based on current usage trends and clinical trial data, there is a high (80%) likelihood of expanded indications for empagliflozin in the treatment of chronic kidney disease.
Antidiabetic, SGLT2 Inhibitor
Benzopyran derivative